Implementation Subcommittee News Today

Study presents new persistence analysis of FINTEPLA, evaluating the efficacy and tolerability of FINTEPLA over a span of 12 months1 Real-world data looks into the need for resources to support caregivers – both parents and siblings – of people living with developmental and epileptic encephalopathies such as Dravet and Lennox-Gastaut syndromes in the transition from […]

Pharmacists play a key role in the management of modern monoclonal antibody treatments for Alzheimer disease.

/PRNewswire/ -- UCB (Euronext: UCB), a global biopharmaceutical company, today announced the U.S. Drug Enforcement Administration (DEA) has published a final...

FINTEPLA® has demonstrated efficacy in the most difficult-to-treat seizure types,1,2 including drop seizures, which cause a person to suddenly lose muscle...